Close Menu

NEW YORK – A team led by University of Kansas researchers has launched a National Institutes of Health-funded validation study to see if a microfluidic cell-capture and phenotyping assay could be used instead of invasive bone marrow aspirates to identify early cases of hematological cancers. 

Led by Steven Soper, a chemistry and mechanical engineering professor at the University of Kansas, the team aims to identify acute lymphoblastic leukemia (ALL) biomarkers in circulating leukemia cells (CLCs). 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.